48m
Isofol Medical AB: Isofol initiates last dose cohort in ongoing phase Ib study with arfolitixorin
GOTHENBURG, Sweden, July 8, 2026 - Isofol Medical AB (publ), (Nasdaq Stockholm: ISOFOL), announces today that the company has completed the third dose level in the dose-escalation part of the phase Ib ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results